Enhancing Electronic Health Record Data Quality

By Michael Awood

September 6, 2023

Electronic Health Record (EHR) data in biomedical research has seen a significant surge, especially during the COVID-19 pandemic. These rich data records are perfect for complex analyses, including machine learning and artificial intelligence. However, the quality of this data has drawn much concern.

Despite the critical role EHR data plays in healthcare and its frequent use in biomedical research, its quality is often overlooked. This presents a need for a standardised approach to evaluate EHR data quality.

In 1996, Wang and Strong proposed a data quality framework that covered intrinsic, contextual, representational, and accessible data quality. They highlighted that poor data quality could have social and economic impacts. Although their study was not healthcare-specific, their framework focused on the needs of data users, providing a unique perspective.

A 2013 review identified five aspects of EHR data quality – completeness, correctness, concordance, plausibility, and currency. They evaluated these aspects through seven methods, including a gold standard comparison and data element agreement. However, the definitions of these methods and dimensions often overlapped, indicating the need for a more standardised approach. Other data quality frameworks have been suggested, but they differ in their recording and discussion methods. This shows a lack of consensus and adoption.

The development of automated tools for data quality assessment holds the potential to address the data quality challenge. These tools could streamline the process and enhance efficiency. The article suggests that future research should aim at creating tools that improve data integrity and reliability in patient care and research. The potential impact of this work is vast, with implications for disease tracking, patient care, and the advancement of medical science.

It is important that EHRs reflect true and accurate data to minimise potential downstream inefficiencies – due to poor data. This data also feeds into prediction analytics or algorithms for various AI systems, where poor data could result in incorrect analytics and poor outcomes. At present, there are numerous entry points to an EHR due to the multitude of records. Data sources include researchers, medical providers, and increasingly, patients through patient-reported outcome measures (PROMs). Utilising the framework by Wang and Strong could provide a better understanding of data needs, leading to improved health records and health information exchanges (HIEs).

Reference url

Recent Posts

lenacapavir HIV PrEP access
    

Global Health Partnerships Unite to Expand Access to Lenacapavir for HIV Prevention

💉 How can we ensure equitable access to HIV prevention methods like lenacapavir?

A recent initiative from the Global Fund, supported by key global health organizations, aims to provide affordable access to this new HIV pre-exposure prophylaxis medication.

With a goal to reach 2 million individuals over three years, this coordinated effort seeks to drastically cut HIV infections and align with our commitment to ending AIDS by 2030.

Explore the details of this impactful collaboration and how it could transform HIV prevention.

#SyenzaNews #globalhealth #HealthcareInnovation #MarketAccess

antimicrobial resistance africa
     

Africa’s Health Crisis: Antimicrobial Resistance and Mpox Outbreak

🌍 Are we prepared to tackle the hidden pandemic of antimicrobial resistance (AMR) in Africa?

With AMR rapidly becoming a dominant health crisis, it’s critical to understand its impact on our healthcare systems and most vulnerable populations.

The Africa CDC highlights the urgent need for substantial investment and coordinated responses to combat this escalating threat, alongside the ongoing Mpox outbreak.

Discover the pressing challenges and potential solutions in our latest article.

#SyenzaNews #GlobalHealth #HealthcareInnovation #AntimicrobialResistance #PublicHealth

BioSapien cancer drug delivery
    

BioSapien Innovative Cancer Drug Delivery Solutions

🌟 How is innovation in drug delivery shaping the future of cancer treatment? 🌟

Discover how UAE-based BioSapien is transforming the healthcare landscape with the MediChip™ platform, securing $5.5 million in pre-Series A funding to enhance cancer care.

This innovative solution promises to minimise side effects and improve treatment outcomes for patients, fully embracing the potential of biotechnology in the fight against cancer.

Read more about BioSapien’s journey and its impact on global health!

#SyenzaNews #biotechnology #oncology #innovation #HealthTech

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2024 Syenza™. All rights reserved.